A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.

The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an increasing clinical importance, thanks to their specificity, efficacy and relative easiness of use. However, in the context of Epstein-Barr virus (EBV)-related malignancies, only cancers of B-cell origin can benefit from therapeutic mAb targeting specific B-cell lineage antigens. To overcome this limitation, we generated a new mAb specific for BARF1, an EBV-encoded protein with transforming and immune-modulating properties. BARF1 is expressed as a latent protein in nasopharyngeal (NPC) and gastric carcinoma (GC), and also in neoplastic B cells mainly upon lytic cycle induction, thus representing a potential target for all EBV-related malignancies. Considering that BARF1 is largely but not exclusively secreted, the BARF1 mAb was selected on the basis of its ability to bind a domain of the protein retained at the cell surface of tumor cells. In vitro, the newly generated mAb recognized the target molecule in its native conformation, and was highly effective in mediating both ADCC and CDC against BARF1-positive tumor cells. In vivo, biodistribution analysis in mice engrafted with BARF1-positive and -negative tumor cells confirmed its high specificity for the target. More importantly, the mAb disclosed a relevant antitumor potential in preclinical models of NPC and lymphoma, as evaluated in terms of both reduction of tumor masses and long-term survival. Taken together, these data not only confirm BARF1 as a promising target for immunotherapeutic interventions, but also pave the way for a successful translation of this new mAb to the clinical use.

antibody-dependent cell-mediated cytotoxicity

complement-dependent cytotoxicity

complete Freud adjuvant

cytotoxic T lymphocytes

Epstein-Barr virus

enzyme-linked immunosorbent assay

human colony-stimulating factor

incomplete Freud adjuvant

interferon-α

luciferase-encoding lentiviral vector

monoclonal antibodies

natural killer

nasopharyngeal carcinoma

polyethyleneglycol

post-transplant lymphoproliferative disease

polyvinylidene fluoride

recombination-activating gene

severe combined immunodeficiency

Introduction

The Epstein-Barr virus (EBV) is a γ-herpesvirus associated with the development of both lymphoid and epithelial malignancies, each characterized by a distinct pattern of viral protein expression. Since viral proteins are expressed almost exclusively in malignant cells, they represent an ideal target for immunotherapeutic strategies, as demonstrated by the success of EBV-specific adoptive T-cell therapy, especially against post-transplant lymphoproliferative disease (PTLD) in which the full array of latent EBV proteins is expressed. However, albeit highly heterogeneous, the infused cytotoxic T lymphocytes (CTLs) are able to target only a few subdominant EBV antigens, such as LMP-1 and LMP-2, thus accounting for the less satisfactory results obtained against tumors characterized by a restricted pattern of latent protein expression.

One of these “neglected” proteins is represented by BARF1, which recently proved to be a very attractive target for improving adoptive immunotherapy of nasopharyngeal carcinoma (NPC). Unlike classic EBV tumor-associated latency proteins, BARF1 is mainly considered an early lytic protein in a normal B-cell background, whereas it is consistently expressed during latency in EBV-related NPC and gastric carcinoma (GC). Whether BARF1 is also expressed in EBV latently infected lymphoma cells, remains to be elucidated.

BARF1 is a 221 amino acid (aa) transmembrane protein expressed at the surface of EBV-infected cells, although the extracellular domain can be cleaved after the first 20 aa and shed, thus exerting its pleiotropic functions both in cis and in trans. Indeed, BARF1 was shown to immortalize simian and human epithelial cells, and human B lymphocytes. Importantly, mouse fibroblasts immortalized upon BARF1 transfection-induced tumors when injected in newborn rodents. Ectopic expression of BARF1 or treatment of cells with its secreted form were shown to promote the growth of different cell types, including mouse fibroblasts, human B cells, primary monkey and human epithelial cells. Interestingly, this autocrine/paracrine cell growth promotion can be blocked by anti-BARF1 antibodies.

Immortalizing and transforming properties of BARF1 are dependent on the activation of various intracellular signaling pathways including c-myc activation, induction of cyclin-D expression, upregulation of the anti-apoptotic molecule Bcl−2, and SMAD4 suppression through NF-κB-mediated miR-146a upregulation. In addition, due to a limited homology with the human colony-stimulating factor 1 (hCSF1) receptor, BARF1 may act as an allosteric decoy receptor for hCSF1, thereby interfering with human monocyte and macrophage differentiation and activity via down-modulation of surface marker expression, reduction of cell viability and IFNα release. By manipulating monocyte and macrophage physiology, BARF1 may therefore exert an immune-modulating role thus contributing to render the tumor invisible to the immune system.

On these grounds, BARF1 can be regarded as an ideal candidate for a monoclonal antibody (mAb) therapy, both in its membrane-associated and shed forms. We therefore aimed at developing a novel BARF1-specific mAb for passive immunotherapy of EBV-related malignancies. In this regard, BARF1-specific polyclonal and monoclonal antibodies described thus far have not been tested for immunotherapeutic approaches. Here, we describe the successful generation of a BARF1-specific monoclonal antibody and its in vitro and in vivo functional characterization. The mAb proved to be effective in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) assays against a panel of BARF1-positive tumor cells. Moreover, biodistribution analysis exploiting in vivo fluorescence imaging demonstrated its specific targeting to EBV-related tumor masses. In immunotherapy experiments involving BARF1-positive NPC and lymphoma preclinical models, the mAb restrained tumor growth and improved long-term survival of treated animals.

Taken together, these data corroborate the role of BARF1 as a novel EBV-specific tumor antigen suitable for immunotherapeutic approaches, and support the concept that anti-BARF1 mAb can be regarded as promising new tools for the treatment of most EBV-related malignancies.

Results

Immunization and monoclonal antibody production

Conventional BALB/c mice were immunized with KLH-conjugated peptides (BARF1201–221, BARF1104–120 and BARF128–38; Fig. 1A) according to a routine schedule, and sera were collected and analyzed by ELISA test. All the peptides used for immunization induced strong antibody production that resulted in elevated absorbance values even at very high sera dilutions (data not shown), thus demonstrating the immunogenicity of the KLH-conjugated peptides. Since BARF1 is expressed on the surface of EBV-infected cells, we decided to use GRANTA-519 cell line, a human mantle lymphoma cell line expressing EBV and BARF1 mRNA, to screen mouse sera by flow cytometry. After the first round of three immunizations, GRANTA-519 resulted negative, thus requiring additional immunizations of mice before a detectable signal was evident. Interestingly, peptide-specific immunoglobulin titres, as assessed by ELISA, remained almost at the same maximal levels, indicating that antibody titres did not increase but improved in terms of intrinsic affinity and ability to recognize naturally folded epitopes that are physiologically presented on the cell surface. After hybridoma generation from the best reactive mouse, the same ELISA and flow cytometry-based screenings were also adopted to analyze the derived clones, ultimately leading to the selection of a single clone (3D4, an IgG2a-secreting hybridoma derived from a mouse immunized with peptide BARF128–38) that was chosen for subsequent analyses.

Figure 1.

BARF1 mAb generation and characterization. (A) Left: BARF1 sequence (NCBI Reference Sequence: YP_401719.1) and derived peptides. Right: dot Blot analysis. Peptides BARF1201–221, BARF1104–120 and BARF128–38 are highlighted in the amino acidic sequence of the whole protein. A positive staining was detected only on peptide BARF128–38 and the derived BARF128–35, thus identifying the minimal epitope of the selected antigen. (B) Flow cytometry analysis of BARF1 expression by GRANTA-519, C-666, BL-41 B95.8, SNU-719, BJAB, RAJI and BL-41 cell lines. (C) Flow cytometry analysis of BARF1 expression by MKN-45 cells before and after transduction with a BARF1-coding retrovirus.

As a first proof of BARF1 target recognition, the 3D4 antibody was used in a Dot Blot assay. All the peptides used for immunization, and two 4-aa overlapping peptides derived from peptide BARF128–38, were spotted on PVDF to identify the epitope recognized by anti-BARF1 antibody. Dot blot analysis revealed that the 3D4 mAb did not recognize unrelated peptides (BARF1201–221 and BARF1104–120), while the BARF128–38 peptide was positively stained. Of the two additional peptides derived from peptide BARF128–38, only peptide BARF128–35 was recognized by the 3D4 mAb, thus indicating that the recognized epitope resides within its sequence (Fig. 1A). BLAST analysis revealed that the peptide sequence is specific for the BARF1 protein and for the human colony-stimulating factor 1 receptor (hCSF-1 receptor), which is known to share homology with BARF1 protein.

The 3D4 mAb specifically identifies BARF1 on tumor cell lines of different histotypes

The anti-BARF1 3D4 mAb stained EBV+BARF1+ tumor cell lines belonging to different histotypes, whereas EBV-negative and BARF1-negative cells were not stained (Fig. 1B). Notably, the EBV+ Raji cell line was not recognized by the 3D4 mAb, consistently with its negativity for BARF1 expression due to a deletion in the corresponding gene within the EBV genome, thus further supporting the specificity of the mAb. The differences in the mean fluorescence intensity observed among the positive cells are likely to be ascribed to the differential expression of BARF1. Indeed, few information is available about BARF1 expression levels on the cell surface, so that we may expect a differential protein expression on different cell lines, or on the same cell line but at different culture stages (in fresh medium rather than in an exhausted, acidified medium). Moreover, cleavage of the extracellular BARF1 domain has been reported, even though the cleavage rate is still to be elucidated.

To further confirm the specificity of the antibody for its target, we ectopically expressed BARF1 in the EBV-negative MKN-45 GC cell line. As shown in Fig. 1C, the 3D4 mAb clearly labeled BARF1-transduced MKN-45 cell line, whereas parental cells showed only background staining, thus demonstrating the fine specificity of the mAb.

The 3D4 mAb mediates both CDC and ADCC in vitro

Complement-dependent cytolysis (CDC) was assessed in a standard chromium release assay, using both EBV-positive and -negative cell lines as target cells. As shown in Fig. 2A, EBV-positive cell lines (GRANTA-519, C-666, BL-41 B95.8 and SNU-719) were specifically lysed when exposed to both 3D4 mAb and complement; in the same experimental conditions, the EBV-negative BL-41 cell line showed only a background level of lysis.

Figure 2.

BARF1 mAb in vitro functional activity. (A) CDC. Specific lysis of EBV-positive (GRANTA-519, C-666, BL-41 B95.8 and SNU-719) and -negative (BL-41) cell lines after exposure to the 3D4 anti-BARF1 mAb and Complement. The isotype control and Complement alone were used as negative controls. (B) ADCC. Specific lysis of EBV-positive and EBV-negative cell lines after exposure to the 3D4 anti-BARF1 mAb and human PBMC from healthy donors. The isotype control and PBMC alone were used as negative controls. Data from three independent experiments were analyzed by Students's t-test and data are reported in the figure as mean ± SD.

ADCC was performed using Calcein AM on the same panel of EBV-positive and -negative cells already used in CDC, with PBMC from healthy donors serving as effector cells. As shown in Fig. 2B, the 3D4 mAb was able to specifically mediate ADCC of BARF1+ target cells. The highest level of lysis of BARF1-positive target cells was obtained with 20 μg/mL of the 3D4 mAb at an effector:target ratio of 300. As evaluated by flow cytometry, the percentage of CD16+CD56+ NK cells in PBMC was in the range of 12–15% of the total population (data not shown).

The 3D4 mAb specifically targets BARF1-positive tumors in vivo

Biodistribution analysis and in vivo targeting capacity of the mAb were assessed by tracking the fluorescence signal of Alexa-680-conjugated anti-BARF1 antibody, following injection in mice grafted with EBV-positive (C-666) or -negative (MKN-45) cell lines at two distinct sites. The analysis was performed daily for 1 week, and the values of fluorescence intensity were recorded for the two tumor masses. As previously reported, a whole intact mouse mAb requires at least 3 d to accumulate differentially at the site of antigen-expressing tumor; indeed, by day 3, the 3D4 mAb showed a markedly higher accumulation at the site of BARF1+ C-666 tumor mass, as compared with the EBV-negative counterpart (Fig. 3A). As an additional proof of specificity, the same biodistribution analysis was performed in mice injected at two distinct sites with untransduced or BARF1-transduced MKN-45 cells. Again, a strong and highly specific signal could be progressively detected only from the BARF1+ MKN-45 cancer mass (Fig. 3B), thus indicating that the 3D4 mAb is specific for the BARF1 protein and capable of recognizing the viral antigen also in vivo.

Figure 3.

BARF1 mAb in vivo biodistribution by fluorescence analysis. Left panels show a representative SCID mouse injected s.c. on one flank with C-666 NPC cells and on the opposite one with MKN-45 GC cells (A), or with MKN-45 GC cells and BARF1-transduced MKN-45 GC cells (B), at two distinct sites. After i.v. injection of Alexa680-conjugated anti-BARF1 mAb, the fluorescence was analyzed at different time points thereafter. Right panels show the histogram representation of fluorescence intensity (p/sec). The experiment was repeated twice with consistent results.

Administration of 3D4 mAb to tumor-bearing mice restrains primitive cancer growth and reduces metastatic spreading

Tumor cell lines of different histotypes were injected in SCID mice either s.c. or i.v. to evaluate the therapeutic activity of anti-BARF1 antibody in tumor mouse models. In the C-666 cell s.c. model, the 3D4 mAb treatment strongly decreased primary tumor growth (p < 0.001; Fig. 4A), relative to the control. Conversely, in mice injected s.c. with the EBV+ BARF1-negative Raji cells, the treatment did not produce any therapeutic effect (data not shown), consistent with in vitro results.

Figure 4.

Therapeutic activity of BARF1 mAb in a NPC mouse model. On day 0, (A) SCID mice and (B) RAG−/− γ-chain−/− mice were injected s.c. with 5×106 C-666 cells. Mab-treated mice (n = 9) received a total amount of 1 mg of the 3D4 anti-BARF1 antibody (white circles) starting at day 10 (palpable tumor), while control animals (n = 5) were injected with PBS only (black squares). The therapy with the antibody significantly delayed the tumor growth (p < 0.001) in A), while no effect was observable in (B) (p = 0.77). (C) Bioluminescence analysis of SCID mice injected i.v. at day 0 with 3×106 C-666-LUX cells, and receiving anti-BARF1 mAb (1 mg) treatment according to the previous schedule. Left panel refers to two representative treated and control mice 8 weeks after cell injection. Right graph shows cumulative BLI data from all animals (control = 10 mice, treated = 12 mice) at different time points of analysis. Mab treatment significantly reduced tumor growth (p = 0.02). (D) Kaplan-Meier survival curves of mice reported in (C): anti-BARF1 mAb therapy significantly increased survival (p = 0.03).

The C-666 cell line was also injected s.c. in RAG−/− γ-chain−/− mice (which lack functional B, T and NK cells), but no difference in cancer growth was observed between treated and control group (p = 0.77; Fig. 4B), thus suggesting that the main effector mechanism of the 3D4 mAb in vivo likely relies on NK cells and ADCC.

To assess the systemic and metastatic behavior of the same cell line upon i.v. injection, we took advantage of a bioluminescent model based on C-666 cells transduced with a luciferase reporter gene. Under these experimental conditions, treatment with the 3D4 mAb provided further strong evidence of therapeutic activity, as tumor growth was heavily delayed in treated mice as compared with control animals and the metastatic progression almost completely abrogated (p = 0.02; Fig. 4C). Moreover, mAb activity impacted on survival that significantly improved in treated vs. control mice (p = 0.03; Fig. 4D).

A similar approach was also adopted to assess the therapeutic effects of 3D4 mAb in a different tumor model represented by the s.c. or systemic injection of the GRANTA-519 cell line. Upon s.c. inoculation, tumor growth was fast in the control group, while appeared significantly reduced in mAb-treated mice (p < 0.001; Fig. 5A). As for the C-666 model, when performed in RAG−/− γ-chain−/− mice the same assay did not bring about any significant difference in GRANTA-519 tumor growth (p = 0.14; Fig. 5B), thus underlying the importance of ADCC as a functional mechanism of anti-BARF1 antibody. When luciferase-transduced GRANTA-519 cells were administered i.v., the treatment with the anti-BARF1 mAb again dramatically restrained tumor growth and dissemination (p = 0.03, Fig. 5C), and led to an improved survival (p = 0.002; Fig. 5D).

Figure 5.

Therapeutic activity of BARF1 mAb in a lymphoma mouse model. On day 0, (A) SCID mice and (B) RAG−/− γ-chain−/− mice were injected s.c. with 5×106 GRANTA-519 cells. Mab-treated mice (n = 13) received a total amount of 1 mg of the 3D4 anti-BARF1 antibody (white circles) starting at day 14 (palpable tumor), while control animals (n = 9) were injected with PBS only (black squares). The therapy with the antibody significantly delayed the tumor grow (p < 0.001) in (A), while no effect was observable in B) (p = 0.14). (C) Bioluminescence analysis of SCID mice injected i.v. at day 0 with 3×106 GRANTA-519-LUX cells, and receiving anti-BARF1 mAb (1 mg) treatment according to the previous schedule. Left panel refers to two representative treated and control mice 3 weeks after cell injection. Right graph shows cumulative BLI data from all animals (10 mice/group) at different time points of analysis. Mab treatment significantly reduced tumor growth (p = 0.03). (D) Kaplan-Meier survival curves of mice reported in (C): anti-BARF1 mAb therapy significantly increased survival (p = 0.002).

Discussion

The dual tropism of the oncogenic EBV for B lymphocytes and epithelial cells reflects on the development of both lymphomas and carcinomas. Among them, only B-cell lymphomas can take advantage of mAb therapy, being successfully treated by targeting some lineage-specific markers such as CD20, CD22, CD30, CD37, CD52, and CD79a. However, these antibodies do not discriminate between normal and malignant cells, thus leading to the possible development of cytopenias and hypogammaglobulinemia. In addition, a significant percentage of patients develops resistance. To overcome these limitations, we identified the viral protein BARF1 as a specific and shared target for a mAb therapy against potentially all EBV-related tumors, since it is expressed as latency protein in EBV-driven carcinomas as well as in lymphomas, at least as an early lytic protein in these latter tumors. Further studies are, however, required to conclusively assess the expression of BARF1 protein in EBV latently infected lymphoma cells. Moreover, BARF1 was recently demonstrated to be a good target for cell-based immunotherapeutic strategies. Despite the fact that this protein is considered poorly immunogenic, nevertheless both humoral and cellular immune responses have been described in NPC patients. Of note, EBV-specific CTL responses appeared to be protective to some extent in a particular cohort of NPC patients, where the HLA molecules that efficiently present CTL epitopes turned out to be significantly under-represented as compared with the general population. Furthermore, BARF1-enriched EBV-specific CTL cultures can be successfully generated through minimal modification of the protocol currently used in clinic.

In the present work, we described the generation and functional characterization of a new mouse mAb (3D4) that specifically recognizes a BARF1 minimal epitope (aa 28–35) located at the N-terminus of the molecule, in the region mediating malignant cell transformation and Bcl−2 upregulation. This characteristic differentiates the 3D4 mAb from other reported BARF1-specific antibodies, which preferentially target the C-terminus of the molecule. More importantly, our results indicate that the 3D4 mAb recognizes the target antigen in its native conformation on the surface of tumor cell lines, as assessed by flow cytometry and functional tests. The detection of BARF1 protein in tumor specimens by immunohistochemistry was, however, frustrated by negative results, probably due to fixation-dependent conformation loss, and/or shedding of the molecule, as previously reported for other mAbs. Our functional in vitro characterization showed that the 3D4 mAb is able to specifically and effectively mediate both CDC and ADCC activity against a panel of selected cell lines, whose entity paralleled the intensity of BARF1 expression. In vivo biodistribution analyses disclosed a specific and long-lasting accumulation (up to 6 d) of the mAb on BARF1-expressing tumors, a critical pre-requisite for the therapeutic activity of a mAb. Moreover, our in vivo experiments demonstrated that the 3D4 mAb is able to exert a significant therapeutic activity in both loco-regional and disseminated in vivo mouse models of NPC and lymphoma. While NPC consistently express BARF1 along with the LMP1 oncoprotein, the chosen model for EBV-driven B-cell lymphoma (i.e., GRANTA-519 cell line) is peculiar considering that it is still unclear whether BARF1 can be expressed by latently infected lymphoma cells in vivo. Available data, however, support the rationale for the use of BARF1 targeting antibodies for the treatment of EBV+ lymphomas. In fact, BARF1-specific mAb therapy for lymphoma patients could be associated and synergize with lytic cycle inducers, such as doxorubicin. Albeit at different extents, tumor-bearing mice treated with anti-BARF1 mAb underwent a significant inhibition of tumor mass growth and experienced an improved survival, when compared with control groups. Noteworthy, in the GRANTA-519 cell line model, i.v. injection of anti-BARF1 antibody induced the complete regression of the mass in 2/10 of treated mice. The lack of any therapeutic effect shown in RAG−/− γ-chain−/− mice strongly indicates that the in vivo activity of the 3D4 mAb is mainly dependent on its ability to mediate ADCC, as also described for BARF1-specific antibodies from NPC patient sera. In addition to these direct effects on tumor cells, we could also expect an indirect antitumor activity. Indeed, unlike BARF1-specific CTL therapy that can only targets antigens correctly presented at the cell surface in a MHC-restricted context, BARF1-specific mAbs could also recognize and block soluble molecules, thus potentially hampering the mitogenic and immune-modulating activity of BARF1 molecules shed in the tumor microenvironment. In particular, since the mAb recognizes an epitope near the aa involved in the interaction with hCSF-1 (aa 38–4118), it can be expected to influence this link by sterical hindrance and potentially relieve the inhibitory activity of BARF1 on monocytes. This aspect is of particular interest in the case of NPC, where the infiltration with mononuclear cells correlates with patient survival. Unfortunately, in the mouse models used in the present study, this potential additional benefit cannot be appreciated, because BARF1 does not interfere with the signaling mediated by mouse CSF1R and CSF1 molecules. Despite this limitation, these promising therapeutic results prompted us to broaden the use of this new tool to other EBV-related malignancies. Indeed, we obtained evidence that lymphoblastoid B cells (LCL, the in vitro model of PTLD) are also positively stained by our anti-BARF1 3D4 mAb (data not shown).

Taken together, these data further substantiate the role of BARF1 as a novel EBV-specific antigen suitable for immunotherapeutic approaches, and provide evidence indicating that the 3D4 anti-BARF1 mAb can be a potent tool for the detection and treatment of several EBV-associated malignancies.

Materials and methods

Cell lines

The following human cell lines were used: GRANTA-519 (mantle B cell lymphoma, EBV+), C-666 (NPC, EBV+), BL-41 (Burkitt lymphoma, EBV−), BL-41 B95.8 (the same cell line infected with EBV), Raji (B lymphoblast-like cell, EBV+, but BARF1−), Bjab (Burkitt lymphoma, EBV−), SNU-719 (GC, EBV+) and MKN-45 (GC, EBV−). All cell lines but SNU-719 and MKN-45 were cultured in RPMI-10 (RPMI 1640 medium, Euroclone, with 10% heat-inactivated Foetal Bovine Serum, FBS, Gibco, 10 mM HEPES Buffer, 1 mM Na Pyruvate, 2 mM Ultraglutamine, all from Lonza BioWhittaker, and 1% Antibiotic/antimycotic, Gibco). SNU-719 and MKN-45 were cultured in DMEM-10 (DMEM medium supplemented with the same additives).

Antibody production

BARF1 sequence was analyzed using bioinformatic tools to select potential exposed epitopes that could be accessible for antibody binding. Three peptides derived from the main potentially immunogenic epitopes were designed for immunization, namely CVGKNDKEEAHGVYVSGYLSQ (BARF1201–221), CRMKLGETEVTKQEHLS (BARF1104–120) and RVTLTSYWRRV (BARF128–38), corresponding to aa sequence of BARF1 protein 201–221, 104–120 and 28–38, respectively. An additional residue of cysteine was added at the N-terminal tail of peptide BARF128–38 to favor the conjugation to the carrier.

The peptides were synthesized at CRIBI (Padua University) by solid-phase technique using a multiple peptides synthesizer (SyroII, MultiSynTech GmbH) on a pre-loaded Wang resin (100–200 mesh) (Novabiochem, Germany). The fluoren-9-ylmethoxycarbonyl (Fmoc) strategy was used throughout the peptide chain assembly, using O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) as coupling reagent.

Peptides were conjugated to maleimide-activated KLH (Keyhole Limpet Hemocyanin) by using Imject Maleimide Activated mcKLH Kit (Thermo Scientific), and used for mice immunizations. The anti-BARF1 hybridoma was derived by fusing murine NS0 myeloma cells with the spleen cells from a BALB/c mouse that had been immunized once subcutaneously with 100 μg of each KLH-conjugated peptide in Complete Freund Adjuvant (CFA, Sigma-Aldrich) and then twice with 100 μg of each KLH-conjugated peptide in Incomplete Freund Adjuvant (IFA, Sigma-Aldrich). When necessary, additional immunizations were performed in IFA. Splenocytes from the immunized mouse were harvested and fused with NS0 myeloma cells using polyethyleneglycol (PEG, Sigma-Aldrich). Hybridoma clones were screened for BARF1 reactivity by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. For flow cytometry analysis, GRANTA-519 cells were stained with the supernatant of the clones, and subsequently with a secondary FITC anti-mouse antibody (Dako); finally, cells were analyzed using FACSCalibur (BD). Only those clones that gave a positive stain as assessed by flow cytometry were used for the subsequent experiments. Antibody recognition was assessed by Dot Blot. Briefly, we synthesized two peptides with a 4-aminoacid overlap, derived from the original 08/0828–39 peptide (used for all the experiments described here). The peptides and the original 08/0828–39, 05/08201–221 and 06/08104–120 peptides were blotted on a PVDF membrane (Millipore) and stained with the anti-BARF1 mAb. The positive signal was evaluated by chemioluminescence using a ChemiDoc XRS instrument and QuantityOne (vers. 4.6) software (both from BioRad).

Flow cytometry analysis of BARF1 staining

BARF1-negative (BJAB, RAJI, BL-41) and -positive (GRANTA-519, C-666, BL-41 B95.8 and SNU-719) cell lines were stained with the anti-BARF1 mAb. Moreover, we generated a BARF1-transduced cell line by transducing MKN-45 cells with a BARF-1 retrovirus.

Evaluation of complement-dependent cytotoxicity (CDC)

Target cells (6×105 GRANTA-519, C-666, BL-41, BL-41 B95.8 cells and SNU-719) were labeled with 100 μCi Na251CrO4 (PerkinElmer). After addition of 1 μg anti-BARF1 mAb, cells were incubated in 200 μL RPMI-25% Human Serum (non-heat inactivated; Lonza), for 1 h at 37°C. Negative controls (or spontaneous release) were cells without mAb, while for positive control (maximum release) 100 μL Triton 5% (Sigma-Aldrich) were added. Supernatant radioactivity was evaluated by using a γ-ray counter (Cobra Gamma Counting System, Packard Instrument Company). The percentage of specific cell lysis was calculated as follows: 100 × [(A − C)/(B − C)], where A represents an absorbance obtained with test serum (experimental release), C and B the minimum (heat-inactivated serum) and maximum release (with Triton 5%), respectively.

Evaluation of antibody-dependent cell-mediated cytotoxicity (ADCC)

ADCC was performed following Calcein-AM (Invitrogen) protocol. Briefly, 1×106 target cells were re-suspended in 1 mL Hank's Balanced Salt Solution added with 5% FBS (HBSS-FBS) and labeled with 7.5 μL of Calcein-AM 1 mg/mL for 30 min at 37 °C. Cells were then labeled with anti-BARF1 mAb at a concentration of 20 μg/mL, 10 μg/mL and 5 μg/mL, while negative controls were performed with HBSS-FBS only. As a positive control, target cells were lysed with Triton 5%. Cells were seeded, and effector cells were added: freshly thawed PBMC from healthy donors were seeded at different effector-target ratios (300:1, 150:1 and 75:1) for 4 h at 37°C, then 100 μL of supernatant were collected and seeded on a 96-well Black OptiPlate (Nunc). After 15 min at RT, the plate was read at 485 nm using Victor X3 Multilabel Plate reader. Lysis percentage (% Lys) was calculated as in CDC.

Mice

In vivo experiments involved 6- to 8-week-old SCID, RAG−/− γ-chain−/− and BALB/c mice (Charles River Laboratories), which were housed in our Specific Pathogen Free (SPF) animal facility. Procedures involving animals and their care were conducted according to institutional guidelines that comply with national and international laws and policies (D.L. 116/92 and subsequent implementing circulars), and the experimental protocol (project ID: 2/2012) was approved by the local Ethical Committee of Padua University (CEASA). During in vivo experiments, animals in all experimental groups were examined daily for a decrease in physical activity and other signs of disease; severely ill animals (weight loss exceeding 15%, lethargy, ruffled hair, low temperature) were killed by carbon dioxide overdose.

Biodistribution analysis

To study the antibody biodistribution, anti-BARF1 mAb was conjugated to Alexa 680 using SAIVI Rapid Antibody Labeling Kit (Invitrogen), and following the manufacturer's indications. SCID mice were injected s.c. on one flank with an EBV-negative cell line (MKN-45) and on the opposite one with a BARF1-positive cell line (C-666 or BARF1-transduced MKN-45). As soon as both tumors became palpable, 100 μg Alexa-680 anti-BARF1 antibody were injected via tail vein in the anaesthetized animal, and the fluorescence signal was analyzed by total body scanning every 24 h using an MX2 apparatus (ART, Canada), as previously reported.

Assessment of therapeutic efficacy

Six-to-eight-week-old SCID and RAG−/− γ-chain−/− mice were injected s.c. with 5×106 C-666 or GRANTA-519 cells. Mice were then divided into untreated and treated groups, which received PBS or 1 mg anti-BARF1 mAb (5 i.p. injections of 0.2 mL each, one every 2 d), respectively, starting from day 10 or 14 after C-666 or GRANTA-519 tumor injection, respectively. Tumor masses were evaluated every 2 d by measuring maximum and minimum diameter, and tumor volume was calculated applying the formula: (d×d×D)/2, where d and D are the minimum and maximum diameters, respectively. Moreover, tumor cell lines were transduced with a firefly luciferase-encoding lentiviral (LV-LUX) vector as described previously. In different experiments, SCID mice were injected i.v. with 3×106 Luciferase-transduced C-666 or GRANTA-519 cells. Then, treated mice received from day 10 (C-666) or 14 (GRANTA-519) and weekly thereafter 0.3 mg/mouse of anti-BARF1 mAb. Bioluminescence (BLI) images were acquired at different time points after in vivo cell injection using the IVIS Lumina II Imaging System (PerkinElmer). Ten minutes before each imaging session, animals were anaesthetized with isoflurane/oxygen and administered i.p. with 150 mg/kg of D-luciferin (PerkinElmer) in Dulbecco's Phosphate-Buffered Saline (DPBS), and the signal intensity was measured as radiance (photon/sec) using the LivingImage software 3.2 (PerkinElmer). Tumor growth and response to therapy were monitored by BLI and by recording survival.

Statistical analysis

Both for the tumor growth and the BLI analysis, ANOVA for repeated measures test was performed between control and treated group, using MedCalc, version 9.4.2.0. Survival diagrams and analysis of the survival data (using Kaplan-Meier test) were performed with the same statistical software.